Autonomix Medical (NASDAQ:AMIX) Upgraded to Hold at Zacks Research

Autonomix Medical (NASDAQ:AMIX) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

AMIX has been the topic of several other research reports. Maxim Group lowered their target price on shares of Autonomix Medical from $5.00 to $2.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Weiss Ratings raised shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 18th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Autonomix Medical presently has a consensus rating of “Hold” and a consensus target price of $2.00.

Autonomix Medical Trading Down 4.6%

Autonomix Medical stock opened at $0.39 on Tuesday. The stock has a market cap of $2.71 million, a price-to-earnings ratio of -0.11 and a beta of -1.43. The company’s 50-day moving average price is $0.38 and its two-hundred day moving average price is $0.50. Autonomix Medical has a 52 week low of $0.20 and a 52 week high of $2.64.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.